Berlin, Germany

Karel Kranda

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Axxonis Pharma Ag. Active years: 2009.

USPTO Granted Patents = 1 

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2009

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Karel Kranda: Innovator in Migraine Treatment

Introduction

Karel Kranda is a notable inventor based in Berlin, Germany. He has made significant contributions to the field of medicine, particularly in the treatment of migraines. His innovative approach has led to the development of a unique patent that addresses migraine-related headaches and other disorders.

Latest Patents

Karel Kranda holds a patent for "Methods of using 1-allyl ergot alkaloid derivatives to treat migraines." This invention relates to 1-allyl ergot alkaloids and their derivatives, which possess selective antagonistic properties to 5-HT receptors. The patent aims to provide prevention and relief from migraine-related headaches, Parkinson's disease, and disorders of thrombocyte function. He has 1 patent to his name.

Career Highlights

Karel Kranda is associated with Axxonis Pharma AG, a company focused on pharmaceutical innovations. His work at Axxonis Pharma AG has allowed him to explore and develop new treatments that can significantly improve the quality of life for patients suffering from migraines and related conditions.

Collaborations

Throughout his career, Karel has collaborated with talented individuals such as Miroslav Flieger and Jan Cvak. These partnerships have fostered an environment of innovation and creativity, leading to advancements in medical treatments.

Conclusion

Karel Kranda's contributions to migraine treatment through his patented methods highlight his role as an influential inventor in the pharmaceutical industry. His work continues to pave the way for new therapeutic options for patients in need.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…